
Star Health reported a 14% year-on-year growth in net earned premium to INR 43.3 billion, with a projected 12% growth to INR 166 billion for FY26. The company showed improved underwriting performance, reflected in a better combined ratio of 94.8%, claims ratio of 64.8%, and reduced commission ratio. Motilal Oswal maintains a BUY rating with a target price of INR 640, expecting a 32% CAGR in IFRS PAT from FY26 to FY28. The second article lacks substantive content.
The articles primarily present financial analysis and investment recommendations without political framing. The focus is on company performance metrics and market outlook, reflecting perspectives from financial analysts. There is no evident political viewpoint or partisan framing in the coverage.
The sentiment across the articles is generally positive, emphasizing Star Health's growth and improved underwriting results. The first article conveys optimism through investment ratings and target prices, while the second article does not provide substantive content to influence sentiment.
Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.
| Source | Their headline | Bias | Sentiment |
|---|---|---|---|
| moneycontrol | Buy Star Health; target of Rs 640: Motilal Oswal- Moneycontrol.com | Center | Positive |
| moneycontrol | Buy Star Health; target of Rs 650: Emkay Global Financial- Moneycontrol.com | Center | Neutral |
moneycontrol broke this story on 30 Apr, 06:54 am. Other outlets followed.
Well-covered story — coverage matches public importance.
Institutions and figures named across source coverage.
Select a news story to see related coverage from other media outlets.